WS #13299

From 500 msgs · 5 key-dev

The dominant theme remains the US-Iran de-escalation, which is now STABLE-to-ESCALATING in its market impact: Trump confirmed talks with Iran begin Monday, calling off a 'massive attack,' and OPEC+ approved a 188k bpd output increase for September, completing the unwind of 2023 cuts. This drove Brent down ~5-7% to ~$83 and WTI below $80, pressuring energy producers (XOM, CVX) while boosting oil importers and airlines. However, Iran's foreign ministry insists Hormuz will not return to pre-war status and that the Oman deal is separate from reopening the strait, injecting uncertainty that could reverse the oil slump. The yen intervention is confirmed and ongoing: US and Japan jointly intervened for the first time in over a decade, with USD/JPY falling to ~155.2, pressuring Japanese exporters (Nikkei -2.2%) and creating a counter-signal to the weak-yen trend. The AI/chip selloff is ESCALATING: KOSPI fell ~5% on profit-taking after Friday's record surge, with Samsung and SK hynix down ~6.5%, and China's semiconductor index tumbled 5.2% amid a global AI correction. This is partially offset by strong earnings from Amazon (cloud revenue +37%) and Microsoft (Copilot >30M paid licenses), which lifted US futures. Bitcoin slipped under $63k due to a Coldcard wallet exploit draining ~$89M, a crypto-specific negative. AstraZeneca's exploration of a ~$400B merger with Bristol Myers Squibb is a major pharma consolidation signal, though it was already surfaced in the previous cycle and lacks new data this window.

Topics

Key developments

  • Trump calls off Iran strike, announces talks; OPEC+ raises output, oil plunges
  • US and Japan confirm joint FX intervention, yen surges to ~155.2
  • KOSPI plunges ~5% as AI/chip selloff resumes after record rally
  • Coldcard wallet exploit drains ~$89M, bitcoin slips under $63k
  • AstraZeneca explores ~$400B merger with Bristol Myers Squibb (ongoing)